All Stories

Otsuka's Taiho pays $400M for Swiss partner to 'turbocharge' 3 ADCs to clinic

Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate linker platform.

Mar 17, 2025 - 13:18
 0
Otsuka's Taiho pays $400M for Swiss partner to 'turbocharge' 3 ADCs to clinic
Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate linker platform.
Read More

Tags:

Previous Article

Citygate diversifies with launch of new leasing business

Next Article

Q Energy to build 200MW solar PV in Spain

Related Posts

Procedural ‘loophole’ leaves NIH grants frozen, despite orders from federal judge: reports

Procedural ‘loophole’ leaves NIH grants frozen, despite...

Feb 21, 2025  0

Oligonucleotide stops gene expansion process that drives Huntington’s disease: study

Oligonucleotide stops gene expansion process that drive...

Feb 12, 2025  0

Siemens Healthineers plans ‘mega depots’ to bolster US supply chain amid ‘geopolitical uncertainties’

Siemens Healthineers plans ‘mega depots’ to bolster US ...

Feb 19, 2025  0